Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues evaluating a treatment for frontotemporal dementia with granulin mutations.
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway Read More »
Medtronic will be the exclusive U.S. distributor of Contego Medical’s portfolio, which includes a carotid stent system and thrombectomy devices.
Medtronic inks distribution deal with Contego with option to buy firm Read More »
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.
Biogen Submits Offer to Buy Embattled Partner Sage Read More »
On Wednesday, a faith-based group of investors requested UnitedHealth prepare a report looking into how its practices could be leading to “delay or abandonment of medical treatment and serious adverse events for patients.”
Investors ask UnitedHealth for answers about delayed, denied care Read More »
Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage trials. Tavapadon, meanwhile, has been a more rewarding asset for the pharma, clearing three Phase III Parkinson’s studies in 2024.
Among Intra-Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.
Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout Read More »
Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO Read More »
En el año 2024, la temperatura promedio de la superficie de la Tierra fue la más cálida de entre todas las registradas desde que comenzaron a realizarse mediciones sistemáticas. Así se ha determinado en un análisis liderado por científicos de …
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx Read More »
